Amgen shelves early-stage bispecific T cell engager

Amgen has stopped development of a Phase 1 bispecific T cell engager, a type of medicine that is core to its oncology portfolio and for which it has trademarked the BiTE acronym.

The California drugmaker terminated a clinical investigation of its experimental treatment AMG 794 in patients with certain forms…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks